A Major Genetic Factor at Chromosome 9p Implicated in Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Lobar Degeneration (FTLD) by Ilse Gijselinck et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
23 
A Major Genetic Factor at Chromosome 9p 
Implicated in Amyotrophic Lateral Sclerosis 
(ALS) and Frontotemporal Lobar Degeneration 
(FTLD) 
Ilse Gijselinck1,2, Kristel Sleegers1,2, 
Christine Van Broeckhoven1,2 and Marc Cruts1,2 
1Department of Molecular Genetics, VIB, Antwerpen 
2University of Antwerp, Antwerpen 
Belgium 
1. Introduction  
Amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) are two 
fatal neurodegenerative diseases for which effective therapies aiming at delaying, halting or 
preventing the disease are lacking. ALS is the most common motor neuron disorder 
(Rowland & Shneider, 2001) and FTLD has a prevalence close to that of Alzheimer disease in 
the population below age 65 years (Rosso et al., 2003). They are considered as both extremes 
of a spectrum of clinically and pathologically overlapping disorders (Lillo & Hodges, 2009). 
In addition, there is emerging evidence that FTLD and ALS also share common genetic 
aetiologies, suggesting that overlapping disease mechanisms are involved in both diseases. 
Clinically, ALS patients show reduced control of voluntary muscle movement expressed in 
increased muscle weakness, disturbances of speech, swallowing or breathing, as a result of 
progressive upper and lower motor neuron degeneration in motor cortex, brainstem and 
spinal cord, and up to 50% of ALS patients shows mild disturbances in executive functions 
while a minority also develop overt FTLD (Lomen-Hoerth et al., 2003; Ringholz et al., 2005). 
FTLD symptoms include behavioural, personality and language disturbances, and also 
cognitive dysfunctions, due to affected frontal and temporal cortical neurons in the brain. 
FTLD patients may additionally present with typical clinical signs of ALS in a later stage of 
the disease (Neary et al., 1998). Pathologically, although in different neuronal cells, TAR 
DNA-binding protein-43 (TDP-43) is a major constituent of neuronal deposits in both ALS 
and TDP-43 positive FTLD (FTLD-TDP), the most common pathological FTLD subtype 
(Arai et al., 2006; Neumann et al., 2006). Five to 10% of ALS patients and up to 50% of FTLD 
patients has a positive familial history of disease with a Mendelian mode of inheritance 
indicating a significant contribution of genetic factors in disease aetiology. Although the 
exact biochemical pathways involved in ALS or FTLD are still unknown, several molecular 
components were identified in the last twenty years through molecular genetic studies in 
familial and sporadic patients, which are most likely part of a complex network of cellular 
mechanisms. Since these genes explain only a minority of patients, further unraveling the 
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genetic heterogeneity is necessary to identify new therapeutic targets. Mutations causing 
ALS were observed in genes encoding Cu/Zn superoxide dismutase 1 (SOD1) (Rosen et al., 
1993), TDP-43 (TARDBP) (Gitcho et al., 2008; Kabashi et al., 2008; Sreedharan et al., 2008; 
Van Deerlin et al., 2008; Yokoseki et al., 2008), fused in sarcoma (FUS) (Kwiatkowski, Jr. et 
al., 2009; Vance et al., 2009) and angiogenin (ANG) (Greenway et al., 2006), among other 
genes, while in familial FTLD patients mutations in the genes encoding granulin (GRN) 
(Baker et al., 2006; Cruts et al., 2006), the microtubule-associated protein tau (MAPT) 
(Hutton et al., 1998), the valosin-containing protein (VCP) (Watts et al., 2004) and the 
charged multivesicular body protein 2B (CHMP2B) (Skibinski et al., 2005) were found. 
Recent family-based linkage and population-based association studies identified genetic 
factors overlapping between ALS and FTLD. For example, mutations in the ALS genes 
TARDBP and FUS are occasionally found in FTLD patients (Kovacs et al., 2009; Van 
Langenhove et al., 2010) and mutations in the FTLD gene VCP were also detected in ALS 
(Johnson et al., 2010). However, most convincing evidence for the genetic overlap comes 
from the observation that both ALS and FTLD can occur within the same family or within a 
single patient of a family. More than 15 autosomal dominant families with ALS and FTLD 
worldwide are causally linked with a major disease locus at chromosome 9p13-p21 
(ALSFTD2 locus) (Boxer et al., 2010; Gijselinck et al., 2010; Le Ber et al., 2009; Luty et al., 
2008; Momeni et al., 2006; Morita et al., 2006; Pearson et al., 2011; Valdmanis et al., 2007; 
Vance et al., 2006). The minimally linked region in all these families is about 3.6 Mb in size 
containing five known protein-coding genes. Moreover, several recent genome-wide 
association studies (GWAS) in ALS populations from different European origins showed the 
presence of a major genetic risk factor for ALS at the same chromosome 9p region 
(Laaksovirta et al., 2010; Shatunov et al., 2010; van Es et al., 2009). The Finnish study 
narrowed the associated region to a 232 kb linkage disequilibrium (LD) block containing 
three known genes (MOBKL2B, IFNK, C9orf72) and suggested the presence of a major risk 
gene with high penetrance (Laaksovirta et al., 2010). Likewise, a GWAS in FTLD has 
implicated the same region (Van Deerlin et al., 2010). This finding was further confirmed in 
other FTLD and ALS-FTLD cohorts (Rollinson et al., 2011). Together, these data demonstrate 
that ALS and FTLD share a major common genetic factor on chromosome 9p, most likely 
showing high mutation frequencies. Despite all attempts of several research groups, the 
genetic defect(s) underlying both genetic linkage and association to this region have not 
been identified yet.  
In this book chapter we will report and discuss the latest findings in the studies aiming at 
identifying the chromosome 9 gene defect.  
2. Family-based linkage to ALSFTD2 locus on chromosome 9p 
Since the original reports of a Dutch and a Scandinavian ALS-FTLD family linked with 
chromosome 9p21 (Morita et al., 2006; Vance et al., 2006), a growing number of families with 
inherited ALS and FTLD are reported with significant linkage to the ALSFTD2 locus on 
chromosome 9p21 (Boxer et al., 2010; Gijselinck et al., 2010; Le Ber et al., 2009; Luty et al., 
2008; Valdmanis et al., 2007) (table 1). In all these families patients show similar clinical and 
pathological characteristics. Clinically, individuals may present with symptoms of both ALS 
and FTLD, or with ALS or FTLD alone. Pathologically, autopsied patients have TDP-43 
positive type 2 (Sampathu et al., 2006) brain inclusions (Boxer et al., 2010; Gijselinck et al., 
2010; Le Ber et al., 2009; Luty et al., 2008; Morita et al., 2006; Vance et al., 2006). (table 1) 
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The minimal candidate region was previously defined by D9S169 (Luty et al., 2008) and 
D9S1805 (Valdmanis et al., 2007) spanning 7 Mb and was recently reduced to 3.6 Mb 
between D9S169 (Luty et al., 2008) and D9S251 by Boxer and colleagues (2010) (figure 1). 
Therefore, several parts of this study were still investigated in the 7 Mb region. 
 
 
 
 
 
 
 
 
Family Origin Max 
LOD 
score 
at 
9p21 
Mean onset 
age in years 
(range) 
 
Mean 
disease 
duration 
in years 
(range) 
TDP-
43+ 
# ALS # ALS 
+ 
FTLD 
# FTLD References 
Luty Australian 3.41 53 (43-68) 9 (1-16) + 2 2 7 (Luty et al., 
2008) 
DR14 Belgian 3.38 58.1 (51-65) 6.4 (1-17) + 1 0 10 (Gijselinck 
et al., 2010) 
F2 Dutch 3.02 60.3 (39-72) 3.0 (1-8) ND 7 3 2 (Vance et 
al., 2006) 
Que23 Canadian 3.01 55.8 (46-58) 2.4 (1.5-3) ND 5 0 3 (Valdmanis 
et al., 2007) 
VSM20 Irish 3.01 45.7 (35-57) 5.4 (3-10) + 2 3 5 (Boxer et al., 
2010) 
F438 Scandinavian 3.00 55.3 (45-64) 4.3 (1-9) ND 5 0 9 (Morita et 
al., 2006) 
6 families French 8.01 57.9 (40-84) 3.6 (1-8) + 9 12 10 (Le Ber et 
al., 2009) 
Que1 French-
Canadian 
2.51 54.3 (45-63) 4.8 (2-9) ND 5 3 0 (Valdmanis 
et al., 2007) 
Fr104 Spanish 1.55 ND ND ND 4 1 0 (Valdmanis 
et al., 2007) 
F2 North-
American 
1.5 ND ND ND 0 7 0 (Momeni et 
al., 2006) 
Gwent Brittish ND 42.2 (31-52) 3.6 (1-13) + 3 6 0 (Pearson et 
al., 2011) 
F476 North-
American 
ND ND ND ND 2 3 0 (Momeni et 
al., 2006) 
ALS_A American ND ? (35-73) ? (0.5-5) ND 6 0 0 (Krueger et 
al., 2009) 
 
 
 
 
 
 
 
 
 
Table 1. Genetic, clinical and pathological characteristics of ALS-FTLD families linked or 
associated with chromosome 9p21 (ND: not determined; 1summed LODscore in 6 small 
families, not linked separately) 
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Fig. 1. Schematic representation of the chromosome 9p21 ALS-FTLD locus. Upper panel: 
grey bars indicate the minimal candidate regions in all reported significantly linked ALS-
FTLD families, defining a minimal interval of 3.7 Mb between D9S169 and D9S251 
containing five protein coding genes, illustrated with grey lines. Lower panel: associated 
SNPs in ALS and FTLD GWAS are shown in red and LD blocks or finemapped regions of 
these GWAS are indicated with green lines. Three genes are located in the associated region.  
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2.1 Family DR14 
We studied a Belgian 4-generation family (family DR14) with autosomal dominant 
transmission of ALS and FTLD. We collected DNA from 29 family members of whom 3 
patients in generation III and 11 at-risk individuals in generation III and IV each (figure 1). 
Two patients (III.2 and III.12) were diagnosed with FTLD (subtype FTD), while patient III.10 
was diagnosed with ALS (figure 2). The mean age at onset was 58.1  4.2 years (N = 9, range 
51-65 years) and mean disease duration was 6.4  4.9 years (range 1-17 years). The index 
patient was clinically diagnosed with familial FTLD (subtype FTD) and pathological TDP-43 
positive inclusions were observed in the brain (FTLD-TDP type 2 (Sampathu et al., 2006)). 
Mutations in the known genes for ALS and dementia were excluded. (Gijselinck et al., 2010) 
 
 
Fig. 2. The pedigree of DR14 consists of four generations. Left-filled and right-filled symbols 
represent patients with FTLD and ALS respectively. Patients with unspecified dementia are 
indicated with filled symbols. Open symbols represent unaffected individuals or at-risk 
individuals with unknown phenotype. Individuals with unclear phenotype are designated 
with a question mark (?). The arrow indicates index patient III.12. Numbers below the 
symbols denote age at onset and age at death (AAD) for patients and either age at last 
examination (AALE) or AAD for unaffected individuals or individuals with unknown 
phenotype. An asterisk (*) indicates individuals of whom DNA was available. 
2.2 Mutation analyses of known genes and conserved regions, and CNV analysis 
We performed a genome-wide scan using an in-house developed mapping set of 425 
microsatellite markers in 30 multiplex panels with an average distance of 8 cM. Multipoint 
LOD scores were calculated revealing two loci on chromosome 9 and 14: one at chromosome 
9 with a maximal LOD score of 2.71 between D9S1121 and D9S270 and one at chromosome 
14 with the highest LOD score of 2.61 between D14S302 and D14S611. Finemapping of the 
chromosome 9 locus resulted in a significant maximal multipoint LOD score of 3.38 between 
D9S1833 and D9S1121 at 9p21 and segregation analysis defined a candidate region of 64.6 
cM (74.7 Mb) between markers D9S235 and D9S257 on chromosome 9p23-9q21, based on 
two obligate recombinants (figure 3), harboring 271 protein coding genes (Gijselinck et al., 
2010). This region overlaps with the ALSFTD2 locus at chromosome 9p21 but did not reduce 
the minimally linked region. Therefore, we analyzed the 7 Mb overlap region, including the 
minimal locus of 3.6 Mb, for mutations. We sequenced all 27 protein-coding genes, either the 
complete coding sequence of cDNA (N=17) including MOBKL2B, C9orf72, ACO1, DDX58, 
TOPORS, NDUFB6, DNAJA1, SMU1, B4GALT1, BAG1, CHMP5, AQP3, NOL6, UBE2R2, 
UBAP2, WDR40A and UBAP1, or the exons and exon-intron boundaries on gDNA using 
classical sequencing (N=10). cDNA was prepared from lymphoblasts of two patients and 
two healthy control individuals of the family not carrying the disease haplotype, treated 
with or without cycloheximide allowing also the detection of degraded aberrant transcripts. 
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Mutation analysis on cDNA allows not only detecting simple point mutations and small 
insertions/deletions but also exon deletions/duplications and alternative transcripts. 
Similar to other chr9-linked ALS-FTLD families, this mutation analysis did not reveal 
patient-specific novel variants segregating with disease.  
 
 
Fig. 3. Segregation of the 9p23-q21 haplotype in family DR14. Haplotypes are based on a 
selection of 20 informative STR markers at chromosome 9. The black haplotype represents 
the disease haplotype. Haplotypes for deceased individuals were inferred based on 
genotype data obtained in their offspring (between brackets). The disease haplotype was 
arbitrarily set for I.1, and numbers in diamonds indicate the number of genotyped at-risk 
individuals. An asterisk (*) indicates individuals of whom DNA was available. 
Since all coding exons of known genes were excluded for mutations, we selected other 
evolutionary conserved regions and investigated these sequences for the presence of non-
coding variants in evolutionary constrained regulatory elements, e.g. promoters and distant 
regulatory elements or conserved epigenetic sequence motifs, or coding variants in 
unknown novel genes (protein coding or non-coding RNA genes). Using the UCSC-
PhastCons-mammalian-28way track predicting and scoring the presence of conserved 
elements in the genome by comparing the sequence between 28 mammalian species, we 
defined 149 kb of conserved elements throughout the ALSFTD2 locus of 7 Mb. These 
elements were grouped in 1108 clusters with a total sequence of 465 kb and ranked 
according to conservation strength. We performed sanger sequencing in two patients and 
two healthy control individuals of the family not carrying the disease haplotype. In total we 
sequenced 95 kb of highest conserved elements (total of 260 kb clusters) in the 7 Mb region, 
not revealing patient-specific novel variants segregating with disease. Of these, 61 kb of 
conserved regions are located in the minimal candidate region of 3.6 Mb. Using this 
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approach, we excluded mutations in highly conserved regions. However, we did not 
exclude variants in regions with no or low conservation in mammalian species because it is 
well known that a substantial number of primate/human-specific exons exist (e.g. Sela et al., 
2007) and that the location of regulatory elements is not always highly conserved, even not 
in mammals e.g. between human and mouse (Ravasi et al., 2010). 
In addition, we performed chromosome-specific oligo-based array-comparative genomic 
hybridization (array-CGH, Nimblegen) at chromosome 9 with a resolution of about 1kb, on 
the index patient and an independent control individual not carrying the disease haplotype 
to detect copy number variations (CNVs). The CGH data were analyzed by Signalmap 
software (Nimblegen) and the scoring program CGHcall, revealing one large CNV 
(chr9:29082732-29087816) covered by 20 CGH probes. This deletion was confirmed in the 
index patient by six qPCR fragments demonstrating a deleted region of at least 5273 bp 
(chr9:29082677-29087949) (data not shown). It did not segregate with disease in DR14 and 
represented a polymorphism since it was also present in individuals not carrying the disease 
haplotype and since a frequent CNV had previously been reported at this position 
(chr9:29082445-29088195) (Cooper et al., 2008). Consequently, these experiments failed to 
identify a copy number mutation (deletion or insertion) of more than 1 kb (Gijselinck et al., 
2010). Cytogenetics excluded large chromosomal rearrangements. 
Since all these mutation analyses did not reveal the causal mutation, we hypothesized that 
the mutation is most likely unusual with respect to location (extragenic or intronic) and/or 
type (small indel, inversion or other complex rearrangement). Therefore, we performed 
whole genome sequencing in family DR14 and subsequently analyzed sequences or variants 
in the linked region. 
2.3 Whole genome sequencing 
The complete genome sequence of four chromosome 9p disease haplotype carriers of family 
DR14, including two patients and two asymptomatic individuals was determined using next 
generation sequencing technology. These family members were selected such that they have 
a different unaffected haplotype. The sequencing was done with the company Complete 
Genomics (Mountain View CA, USA, www.completegenomics.com) who provides 35 bp 
paired-end sequence reads at a high sequence coverage obtained with high-accuracy 
combinatorial probe anchor ligation (cPAL) sequencing technology (Drmanac et al., 2010; 
Roach et al., 2010). Also, the paired-end sequencing data enable the identification of copy 
number variations (CNVs) and other structural variants (SV) including inversions, in 
addition to single nucleotide polymorphisms (SNPs).  
In the 4 genomes, we obtained an average coverage of 62-fold genome sequence and 
captured both alleles at 95.4% of the genomes. All sequence variants, including SNPs and 
small indels, were mapped to the human reference genome sequence (NCBI Build 
36/hg18). We initially focused on the 3.6 Mb candidate region on chromosome 9p21. We 
filtered and prioritized variants according to several criteria. First, variants must be 
present heterozygously in all 4 patients since the disease is segregating in an autosomal 
dominant manner. As a heterozygous variant might be rarely missed using NGS 
technology, depending on local sequence coverage and quality, variants detected in three 
of four patients were also considered. Second, variants were selected that were not 
catalogued in the dbSNP database (http://www.ncbi.nlm.nih.gov/projects/SNP) and 
were not found as common polymorphisms (allele frequency ≥ 1%) in the 1000 Genomes 
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Project (http://www.1000genomes.org). Third, variants in nucleotide stretches were 
filtered out because they are known to be error-prone in NGS data. This resulted in a 
total of 189 variants, all located outside coding regions of known genes confirming gene-
based mutation analyses. These variants were genotyped in all 29 individuals of the 
DR14 family using Sanger sequencing and tested for segregation. 120 variants were 
located on the disease haplotype and were analyzed in a series of 300 neurologically 
healthy control individuals collected in Flanders, Belgium, i.e. the geographical region of 
which family DR14 originates, using multiplex Sequenom MassARRAY technology. 37 of 
these variants were completely absent in 300 control individuals and are all located in 
untranslated regions or introns of genes, or intergenic. We are currently prioritizing 
these variants based on evolutionary conservation, regulatory potential, location 
compatible with cis-acting function on functional candidate genes, etc. Also, we are 
determining the presence of these variants in a Belgian population of unrelated patients 
with ALS (N=124), ALS-FTLD (N=21) and FTLD (N=203), aiming to find a possible 
founder mutation. We already showed evidence for the presence of founder mutations in 
the Flanders-Belgian FTLD collection, by the GRN IVS1+5 G>C founder mutation 
identified in 19% of familial FTLD (Cruts et al., 2006). We have investigated the patient 
population for chromosome 9p STR markers and did not find evidence for haplotype 
sharing with family DR14; however, we cannot exclude the presence of a small, 
previously undetected founder haplotype.  
3. Population-based association for ALS and FTLD to chromosome 9p  
In 2009, the first ALS GWAS showing association with a locus at chromosome 9p21 was 
reported by Van Es and colleagues. They identified genome-wide significance with two 
SNPs, rs2814707 and rs3849942, almost in complete linkage disequilibrium (LD) with each 
other and located in an LD block of ~80 kb. Also a third SNP in this LD block (rs774359) 
showed suggestive association (figure 1). This LD block is situated at the telomeric end of 
the minimally linked candidate region found in the ALS-FTLD families and contains only 
three genes: part of MOBKL2B, IFNK and C9orf72 (figure 1). Next, data of the first GWAS 
in FTLD-TDP were suggestive for association of five SNPs (rs774352, rs774351, rs3849942, 
rs2814707, rs774359) on chromosome 9p21, in the same LD block (Van Deerlin et al., 2010). 
Subsequently, a Finnish and a British independent ALS GWAS identified genome-wide 
significance with SNPs rs3849942, rs2814707, rs774359, rs2225389 (Laaksovirta et al., 2010) 
and with SNPs rs3849942, rs2814707, rs903603 (Shatunov et al., 2010) respectively, all in 
the same locus at chromosome 9p21. The Finnish study defined a 42-SNP haplotype 
associated with increased risk of ALS in the Finnish population, located in a 232 kb LD 
block which overlaps with the previously reported 80 kb LD block (van Es et al., 2009) and 
the 106.5 kb LD block of the UK study (Shatunov et al., 2010). Because of the unique 
homogeneous genetic structure of the Finnish isolated population, the extent and 
structure of LD is different than in other European countries. To date, one study 
replicated the association of the chr9p21 locus in an ALS-FTLD subpopulation (Rollinson 
et al., 2011). 
To assess the contribution of the chr9p21 risk factor to disease etiology in Belgium, we 
replicated one of the top SNPs associated in all GWAS reports, rs2814707, in a Belgian 
population of ALS, ALS-FTLD and FTLD patients. In addition, we performed a meta-
analysis of the different published association studies with inclusion of our study. 
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3.1 Replication study chr9p21 GWAS 
We investigated association of the most widely studied GWAS top SNP at chr9p21, 
rs2814707, in a Flanders-Belgian population of genealogically unrelated patients clinically 
diagnosed with ALS (N=124), ALS-FTLD (N=21) or FTLD (N=203) according to established 
consensus criteria (Brooks et al., 2000; Neary et al., 1998), compared to a group of 510 
unrelated neurologically healthy control individuals from the same region in Belgium. We 
genotyped rs2814707 and showed that this SNP is in Hardy-Weinberg Equilibrium. Allelic 
and genotypic single SNP association was calculated using logistic regression analysis. The 
SNP showed significant allelic and genotypic association in the total population and highly 
significant association in the ALS and ALS-FTLD subpopulation reaching a maximal odds 
ratio of 3.27 in ALS patients homozygous for the minor allele (table 2). In the FTLD 
subpopulation no association was found, demonstrating that the effect in the total 
population can entirely be explained by the effect in patients with an ALS phenotype. When 
we include 21 ALS samples of Bulgarian origin, the relative risk became even higher, 
compared to Belgians only, indicating that the associated allele is the same between 
different populations. 
 
SNP ID Genotype Controls ALS, ALS-FTLD and FTLD ALS and ALS-FTLD 
  N=510 N=348 N=145 
  freq (%) freq (%) p-value OR (95%CI) freq (%) p-value OR (95%CI) 
rs2814707 C 77.9 71.3 0.006 1.39 (1.10-1.75) 67.0 0.001 1.69 (1.25-2.29) 
 T 22.1 28.7   33.0   
 CC 59.7 50.4 ref ref 43.1 ref ref 
 CT 36.5 41.8 0.08 1.31 (0.97-1.77) 47.9 0.007 1.76 (1.17-2.64) 
 TT 3.8 7.8 0.008 2.41 (1.26-4.62) 9.0 0.005 3.27 (1.44-7.41) 
Table 2. Allelic and genotypic association of a GWAS top SNP in the total population and 
the ALS/ALS-FTLD subpopulation. P-values are corrected for age at onset or inclusion and 
gender. (OR: odds ratio; CI: confidence interval) 
3.2 Meta analysis on chromosome 9p21 
We combined the data from the different GWA studies and our study to determine the 
relative risk of carrying the risk allele on chromosome 9p21. A meta-analysis of the most 
widely studied SNP on chromosome 9p21 (rs2814707) underscores the presence of a genetic 
risk factor for ALS and/or FTLD at this locus. Carriers of the rs2814707 minor allele are at 
increased risk to develop ALS or FTLD (ORmeta 1.29 (95% CI 1.18-1.41), p-value 2.3*10-8 
(Figure 4)).  When excluding the GWAS cohorts in which the association was first reported 
(van Es et al., 2009) to exclude bias because of winner’s curse, the strength of the association 
remains similar (ORmeta 1.32 (95%CI 1.17-1.49; p-value 3.5*10-6). Exclusion of three studies, 
including our own, which combine FTLD and ALS phenotypes would have resulted in an 
ORmeta 1.24 (95%CI 1.13-1.36); p-value 3.3*10-6). 
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Fig. 4. Forest plot of a random effects meta-analysis of rs2814707. Meta-analysis was 
conducted in rmeta v2.16, and based on effect estimates and standard errors for the minor 
allele reported in each individual publication. Odds Ratios and 95% Confidence Intervals 
are given for each study separately along with a summary Odds Ratio, of the minor allele 
relative to the major allele. All 9p21 association studies on ALS, ALS-FTLD and FTLD 
published until July 2011 were included, in addition to our own unpublished data. For the 
study of Shatunov and colleagues we only included data on the independent UK cohort, to 
avoid overlap of datasets with previous studies. From Rollinson et al, only data on the 
Manchester ALS-FTLD cohort are included. 
4. Discussion and conclusion 
Family-based linkage and population-based association studies in Belgian patients with ALS 
and/or FTLD provided further evidence for the presence of a major genetic factor on 
chromosome 9p21 for these diseases.  
In the Belgian family DR14 we analyzed the minimally linked region shared in all linked 
families. We excluded mutations in exons of all known protein-coding genes, in the highest 
conserved sequences and also copy number mutations of more than 1 kb were excluded. 
Further we used next generation sequencing technology to sequence the whole genome of 
four disease haplotype carriers. We are currently analyzing the first selection of variants. If 
we are left with only a very small number of putative disease-associated variants, we will 
analyze the complete sequence of the functional unit in which the remaining variants are 
located in the complete set of ALS, ALS-FTLD and FTLD patients. `Functional unit' in this 
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context means the gene, regulatory element, conserved element or, in the absence of 
recognizable elements, 1 kb flanking each side of the putative mutation. This might identify 
additional mutations resulting in the same functional defect as the mutations detected in 
DR14 and further enhance the likelihood of the variant(s) to be disease-related. Finding such 
variants will provide strong genetic evidence of a disease causing effect of the variants. 
Alternatively, in case we do not find a mutation in this first selection of variants, we can use 
more relaxing filters. Taking into account that dbSNP may include rare clinical variants, rare 
or non-validated dbSNP SNPs will also be considered (N=91). Also the candidate region can 
be extended to the next recombinant or to the large DR14 candidate region. Further, regions 
that are not covered in more than one genome, will be completed using classical sanger 
sequencing. Finally, structural variants and copy number mutations will be investigated. 
More than five years of research in the ALSFTD2 locus in different ALS-FTLD families 
worldwide did not identify pathogenic mutations yet (table 1), although mutations in two 
different genes on chromosome 9 outside the minimal candidate region, IFT74 and 
SIGMAR1, were suggested (Luty et al., 2010; Momeni et al., 2006) but without further 
confirmation in other families. The fact that the culprit gene is still not found may in part be 
explained by the fact that families linked with chromosome 9p21 do not all have the same 
disease haplotype so that different mutations, probably with the same effect on the same 
gene, are most likely involved. Also, the causal mutations are most likely unusual with 
respect to position or type. For example, deep intronic mutations or mutations in a distant 
regulatory element might cause the disease but assessing their effect is rather complicated. 
Also, identification of small insertions/deletions or inversions is challenging.  
In addition, we replicated association in a Belgian cohort of ALS, ALS-FTLD and FTLD 
patients of two major top SNPs on chromosome 9p21 previously associated in several ALS 
and FTLD GWA studies. More specifically, we found that the risk haplotype at chromosome 
9p21 is most substantially increased in patients with ALS or ALS-FTLD compared to control 
individuals. The lack of association in the FTLD subpopulation is similar to what was 
observed in a previous replication study in which association was only found in ALS-FTLD 
patients (Rollinson et al., 2011). Also, the weakest association signal was found in the FTLD 
GWAS compared to ALS GWAS. This is the first time that a susceptibility locus for ALS is 
replicated in different GWA studies and replication studies, underlining the importance of 
the chromosome 9p21 locus harbouring a risk increasing factor for ALS (and ALS-FTLD) 
across multiple populations with a high relative risk of disease susceptibility. We are further 
characterizing this genetic association to reduce the associated region in the Belgian 
population. We are finemapping the chromosome 9p risk haplotype in great detail in our 
ALS, FTLD, ALS-FTLD patient cohorts by making a high density SNP map of the complete 
LD block and using extended association analyses of series of known and newly identified 
variants in the LD block. These variants were identified in previous publications, hapmap, 
1000 Genomes Project and extended genomic sequencing efforts of the linkage 
disequilibrium block in a selection of ALS and ALS-FTLD patients carrying the associated 
allele of the GWAS SNPs in a homozygous or heterozygous state. This will finally result in 
the identification of the functional variant explaining the strong association in the 
chromosome 9p21 region. 
The observation that the chromosome 9p21 region is harboring both disease-causing 
variants and susceptibility factors with high penetrance, might suggest that different genetic 
variants with variable degree of biological consequences might be involved. Alternatively, 
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one genetic defect might act as high penetrant susceptibility factor in sporadic patients and 
as disease-causing factor with reduced penetrance in ALS-FTLD families, carrying also other 
disease modifying factors. In this respect it is interesting to note that in our studied belgian 
family DR14 all patients carry in addition to the disease haplotype at chromosome 9p21 also 
a haplotype in a novel locus at chromosome 14q32, possibly harboring a disease modifying 
gene (Gijselinck et al., 2010) and of which the sequences are present in the whole genome 
sequencing data of the family. Combining the family-based and the population-based 
approach to ultimately find the gene with one or more genetic defects would be of great 
value. For example, prioritizing the associated LD block in the whole genome sequence 
analysis of the family could be useful. Further, since in the associated LD block only three 
genes are located (IFNK, C9orf72, MOBKL2B) (figure 1), we could focus on these genes with 
respect to expression and dosage studies (eg. single exon deletions or duplications) in the 
family. Also, the region in and around the associated LD block can be saturated with STR 
markers for sharing studies with the DR14 family to detect a small founder haplotype. 
Combining all these comprehensive data will bring us closer to the identification of the 
chromosome 9 gene. As long as the genetic defect underlying linkage and association is not 
known, the full epidemiological impact of the chromosome 9p gene in familial and non-
familial forms of ALS, ALS-FTLD and FTLD cannot be determined. However, the combined 
evidence emerging from all molecular genetic studies in chromosome 9p21-linked families 
and in chromosome 9p21 associated ALS/FTLD populations, suggests it is the most 
important genetic factor contributing to disease in the center of the disease spectrum linking 
ALS and FTLD (table 1). Moreover, next to the chr9p21 conclusively linked ALS-FTLD 
families, several other (smaller) families were also reported without conclusive linkage but 
with several indications pointing towards the presence of a segregating haplotype in the 
ALSFTD2 locus (Krueger et al., 2009; Le Ber et al., 2009; Momeni et al., 2006; Pearson et al., 
2011; Valdmanis et al., 2007; Yan et al., 2008) (table 1). Identification of this major gene will 
undoubtedly be a steppingstone for subsequent cell biological studies aiming at better 
understanding of the pathobiology of neurodegenerative processes leading to ALS and 
FTLD. 
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